On the other hand, HMGB-1 levels seem to be positively correlated with symptom severity scores in patients with remission phase of schizophrenia, whereas, the biomarker levels do not relate to symptom scores in acute exacerbation phase. This evidence concerns the gene HMGB1 and schizophrenia.